search
Back to results

Pancreatic Duct Stenting to Prevent Postoperative Pancreatic Fistula (POPF) After Distal Pancreatectomy

Primary Purpose

Pancreatitis

Status
Suspended
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Boston Scientific or Cook pancreatic duct stents
Sponsored by
Kaiser Permanente
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pancreatitis focused on measuring pancreatic fistula, pancreatectomy, endoscopic stenting, pancreatic stenting, distal pancreatectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult patients age 18 years of age and older
  2. Patients undergoing distal pancreatectomy for primary pancreatic disorder or isolated metastases to the pancreas.

Exclusion Criteria:

  1. Pediatric patients younger than age 18
  2. Pregnant patients
  3. Patients undergoing distal pancreatectomies performed en bloc for non- pancreatic pathologies (gastric cancer, renal cell cancer, etc).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    Retrospective and prospective "non-stented"

    Prospective "stented"

    Arm Description

    Non-stented patients undergoing distal pancreatectomy retrospectively (2008-2015) and prospectively from 2015 to 2017.

    Patients who undergo prophylactic pancreatic duct stenting prior to a distal pancreatectomy starting approximately September 2015.

    Outcomes

    Primary Outcome Measures

    Post-operative pancreatic fistula
    Rate of post-operative pancreatic fistula will be evaluated at 6 months when enrollment begins. Early stop is determined under either of below conditions: Effect size is smaller than needed to reach statistical difference even if number of enrollment is completed in one year. Adverse events occurring from the pancreatic duct stenting itself, which include pseudocyst, delaying surgery, pancreatitis requiring prolonged hospital admission, or death. There is statistical significant difference between control and intervention groups.

    Secondary Outcome Measures

    Pre-operative: Pancreatitis from pancreatic duct stent
    Postoperative: Abscess, hemorrhage, reoperation, pulmonary embolism, mortality

    Full Information

    First Posted
    October 7, 2015
    Last Updated
    July 31, 2018
    Sponsor
    Kaiser Permanente
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02573389
    Brief Title
    Pancreatic Duct Stenting to Prevent Postoperative Pancreatic Fistula (POPF) After Distal Pancreatectomy
    Official Title
    A Pilot Study on the Effect of Transampullary Pancreatic Duct Stenting on Postoperative Pancreatic Fistula Rate After Distal Pancreatectomy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2018
    Overall Recruitment Status
    Suspended
    Why Stopped
    lack of accrual due to competing study
    Study Start Date
    December 4, 2015 (Actual)
    Primary Completion Date
    December 2019 (Anticipated)
    Study Completion Date
    January 2020 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Kaiser Permanente

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    To determine whether pre-operative pancreatic stenting for distal pancreatectomy will impact the incidence of a post-operative pancreatic fistula, as defined by postoperative. If pre-operative pancreatic stenting appears to reduce the formation of Postoperative Pancreatic Fistula (POPF) in this pilot study, this will form the basis of a larger randomized trial in the future. The hypothesis is that pre-operative pancreatic duct stenting can significantly decrease the rate of development of a post-operative pancreatic fistula after distal pancreatectomy.
    Detailed Description
    Prophylactic pancreatic duct stenting is to be offered to all patients deemed a candidate for a distal pancreatectomy. This is a nonrandomized cohort study with a retrospective and prospective control group (Jan 2008 - Dec 2017 or sample size obtained) and a prospective endoscopic intervention group (September 2015 - Dec 2017 or until sample size obtained). We will then compare the rate of development of a postoperative pancreatic fistula between those patients who have preoperative stenting and those who do not. POPF will be defined as the amylase level of drain contents equaling three times or more the serum amylase on postoperative day 3, as defined by the International Study Group for Pancreatic Fistula (ISGPF) or an ICD-9 diagnosis of 577.8. The patient will have a pre-operative visit for stent placement and a post-operative visit for stent removal if still in place 4-6 weeks after distal pancreatectomy.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pancreatitis
    Keywords
    pancreatic fistula, pancreatectomy, endoscopic stenting, pancreatic stenting, distal pancreatectomy

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Retrospective and prospective "non-stented"
    Arm Type
    No Intervention
    Arm Description
    Non-stented patients undergoing distal pancreatectomy retrospectively (2008-2015) and prospectively from 2015 to 2017.
    Arm Title
    Prospective "stented"
    Arm Type
    Experimental
    Arm Description
    Patients who undergo prophylactic pancreatic duct stenting prior to a distal pancreatectomy starting approximately September 2015.
    Intervention Type
    Device
    Intervention Name(s)
    Boston Scientific or Cook pancreatic duct stents
    Intervention Description
    Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
    Primary Outcome Measure Information:
    Title
    Post-operative pancreatic fistula
    Description
    Rate of post-operative pancreatic fistula will be evaluated at 6 months when enrollment begins. Early stop is determined under either of below conditions: Effect size is smaller than needed to reach statistical difference even if number of enrollment is completed in one year. Adverse events occurring from the pancreatic duct stenting itself, which include pseudocyst, delaying surgery, pancreatitis requiring prolonged hospital admission, or death. There is statistical significant difference between control and intervention groups.
    Time Frame
    At 6 months when enrollment begins
    Secondary Outcome Measure Information:
    Title
    Pre-operative: Pancreatitis from pancreatic duct stent
    Time Frame
    1 - 2 weeks prior to distal pancreatectomy
    Title
    Postoperative: Abscess, hemorrhage, reoperation, pulmonary embolism, mortality
    Time Frame
    3 days post surgery

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adult patients age 18 years of age and older Patients undergoing distal pancreatectomy for primary pancreatic disorder or isolated metastases to the pancreas. Exclusion Criteria: Pediatric patients younger than age 18 Pregnant patients Patients undergoing distal pancreatectomies performed en bloc for non- pancreatic pathologies (gastric cancer, renal cell cancer, etc).
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Louis A DiFronzo, MD
    Organizational Affiliation
    Kaiser Permanente
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    23043660
    Citation
    Jin T, Altaf K, Xiong JJ, Huang W, Javed MA, Mai G, Liu XB, Hu WM, Xia Q. A systematic review and meta-analysis of studies comparing laparoscopic and open distal pancreatectomy. HPB (Oxford). 2012 Nov;14(11):711-24. doi: 10.1111/j.1477-2574.2012.00531.x. Epub 2012 Aug 7.
    Results Reference
    background
    PubMed Identifier
    25392839
    Citation
    Schoellhammer HF, Fong Y, Gagandeep S. Techniques for prevention of pancreatic leak after pancreatectomy. Hepatobiliary Surg Nutr. 2014 Oct;3(5):276-87. doi: 10.3978/j.issn.2304-3881.2014.08.08.
    Results Reference
    background
    Citation
    3. American Society for Gastrointestinal Endoscopy (ASGE) Technology Assessment Committee. Status evaluation reports: Pancreatic and biliary stents. Gastrointest Endosc. 2013;77(3):319-327.
    Results Reference
    background
    PubMed Identifier
    24019766
    Citation
    Reddymasu SC, Pakseresht K, Moloney B, Alsop B, Oropezia-Vail M, Olyaee M. Incidence of pancreatic fistula after distal pancreatectomy and efficacy of endoscopic therapy for its management: results from a tertiary care center. Case Rep Gastroenterol. 2013 Aug 16;7(2):332-9. doi: 10.1159/000354136. eCollection 2013.
    Results Reference
    background
    PubMed Identifier
    20598301
    Citation
    Rieder B, Krampulz D, Adolf J, Pfeiffer A. Endoscopic pancreatic sphincterotomy and stenting for preoperative prophylaxis of pancreatic fistula after distal pancreatectomy. Gastrointest Endosc. 2010 Sep;72(3):536-42. doi: 10.1016/j.gie.2010.04.011. Epub 2010 Jul 3.
    Results Reference
    background

    Learn more about this trial

    Pancreatic Duct Stenting to Prevent Postoperative Pancreatic Fistula (POPF) After Distal Pancreatectomy

    We'll reach out to this number within 24 hrs